背景：炎症性肠病（IBD）是一种慢性疾病，可以通过治疗来控制，但治愈 IBD 具有挑战性。白藜芦醇是一种从多种植物中提取的非黄酮类多酚有机化合物，对 IBD 有潜在作用。目前的研究旨在调查白藜芦醇对 IBD 动物模型的治疗效果。方法：全面检索 PubMed、Embase、Web of Science 和中文数据库。文献检索过程由两人独立完成，并由第三人审阅。使用实验性卒中动物数据荟萃分析和审查协作方法 (CAMARADES) 10 点质量检查表评估纳入文献中的偏倚风险。荟萃分析利用 Review Manager 5.4 软件评估白藜芦醇的功效，以组织病理学指数作为主要结果指标。根据该指标进行亚组分析。此外，还对文献报道的不同结果进行了荟萃分析，包括最终疾病活动指数、最终体重变化、结肠长度、脾指数和炎症因子。结果：经过彻底的文献检索和筛选过程，最终共有 28 项研究纳入分析。结果发现，超过一半的入选研究在偏倚风险评估中有五个以上具有低偏倚风险的项目。纳入文献相关数据表明，白藜芦醇组的组织病理学指标显着低于对照组（WMD=-2.58[-3.29，-1.87]）。亚组分析显示，较高剂量的白藜芦醇 (>80 mg/kg) 具有更好的疗效 (WMD = -3.47 [-4.97, -1.98])。此外，SI和结肠长度的数据汇总和定量分析结果也表明白藜芦醇可有效减轻IBD的肠粘膜病理损伤。在生化指标方面，总结分析发现，白藜芦醇影响白细胞介素1β（IL-1β）、白细胞介素6（IL-6）、白细胞介素8（IL-8）、白细胞介素10（IL-10）、肿瘤坏死因子-α (TNF-α)、转化生长因子-β (TGF-β)、干扰素-γ (IFN-γ)、丙二醛 (MDA)、髓过氧化物酶 (MPO)、超氧化物歧化酶 (SOD) 和前列腺素 E2（ PGE2) 显着。这些作用可能归因于白藜芦醇调节免疫反应和抑制氧化应激的机制。结论：本综述表明，白藜芦醇在 IBD 临床前模型中表现出显着的治疗作用，特别是在剂量超过 80 毫克/千克时。这种功效归因于通过多种途径参与 IBD 发病机制的针对肠粘膜的保护机制。因此，白藜芦醇在未来的临床应用中具有广阔的前景。版权所有 © 2024 顾、楼、周、赵、叶、吴、李和吉。

Background: Inflammatory bowel disease (IBD) is a chronic condition that can be managed with treatment, but it is challenging to get IBD cured. Resveratrol, a non-flavonoid polyphenolic organic compound derived from various plants, has a potential effect on IBD. The current research was set out to investigate the therapeutic effects of resveratrol on animal models of IBD. Methods: A comprehensive search of PubMed, Embase, Web of Science, and Chinese databases was performed. The literature search process was completed independently by two people and reviewed by a third person. The risk of bias in the included literature was assessed using the Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Stroke (CAMARADES) 10-point quality checklist. The meta-analysis utilized Review Manager 5.4 software to evaluate the efficacy of resveratrol, with histopathological index as the primary outcome measure. Subgroup analysis was conducted based on this indicator. Additionally, meta-analyses were carried out on different outcomes reported in the literature, including final disease activity index, final body weight change, colon length, splenic index, and inflammatory factors. Results: After conducting a thorough literature search and selection process, a total of 28 studies were ultimately included in the analysis. It was found that over half of the selected studies had more than five items with low risk of bias in the bias risk assessment. Relevant datas from included literature indicated that the histopathological index of the resveratrol group was significantly lower than that of the control group (WMD = -2.58 [-3.29, -1.87]). Subgroup analysis revealed that higher doses of resveratrol (>80 mg/kg) had a better efficacy (WMD = -3.47 [-4.97, -1.98]). Furthermore, The data summary and quantitative analysis results of SI and colon length also showed that resveratrol was effective in alleviating intestinal mucosal pathological injury of IBD. In terms of biochemical indicators, the summary analysis revealed that resveratrol affected interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), interferon-γ (IFN-γ), malondialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD), and prostaglandin E2 (PGE2) significantly. These effects may be attributed to the mechanism of resveratrol in regulating immune response and inhibiting oxidative stress. Conclusion: This review suggests that resveratrol demonstrated a notable therapeutic impact in preclinical models of IBD, particularly at doses exceeding 80 mg/kg. This efficacy is attributed to the protective mechanisms targeting the intestinal mucosa involved in the pathogenesis of IBD through various pathways. As a result, resveratrol holds promising prospects for potential clinical use in the future.Copyright © 2024 Gu, Lou, Zhou, Zhao, Ye, Wu, Li and Ji.